This study is testing a new approach for people with locally advanced or metastatic pancreatic cancer. It uses two substances together: [68Ga]Ga DOTA-5G for imaging and [177Lu]Lu DOTA-ABM-5G for treatment. First, you would receive [68Ga]Ga DOTA-5G for a special scan (PET/CT) to see if you're a good candidate for the treatment. If so, you would then receive [177Lu]Lu DOTA-ABM-5G. The main goals are to find a safe and effective dose of [177Lu]Lu DOTA-ABM-5G and to see how well it works. This is a "first-in-human" study, meaning it's one of the first times these substances are being tested in people. About 30 people are expected to join. The study status is unclear.

Study design

This is a Phase I, first-in-human study designed to find the best dose of [177Lu]Lu DOTA-ABM-5G. It plans to enroll about 30 participants.

What's involved

You would undergo PET/CT imaging after receiving [68Ga]Ga DOTA-5G. If eligible, you would then receive doses of [177Lu]Lu DOTA-ABM-5G, with safety checked for 30 days after injection.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be measured for 30 days after receiving the [177Lu]Lu DOTA-ABM-5G treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.